Cannabis Europa is delighted to announce that we will be co-hosting the Australian Medicinal Cannabis Conference 2020 in partnership with Pharmout, taking place 23-24th March in Melbourne. Industry leading investors, medical professionals and key stakeholders from across the Oceania region will be attending to discuss the future of the cannabis industry, as well as the greatest commercial opportunities expected to develop in the coming years.
Dr. Adele Hosseini is Chief Scientific Officer at Bod Australia. She has over 18 years’ experience leading the delivery of successful clinical trials including first in human pharmaceuticals and medical devices. She is a pioneer in the Australian medicinal cannabis industry-leading Bod Australia’s Scientific Advisory Board and research program. Over the last three years Dr. Hosseini has developed a deep understanding of medicinal cannabis and continues to development of new strategic direction and development of clinical trials and programs for pharmaceutical cannabis for multiple therapeutic indications for public health benefit.
Rhys is a recognized thought leader in the Australian medicinal cannabis industry. He has previously worked as a freelance commercial consultant and as Senior Project Officer at the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics. Rhys was the lead author on Australia’s first policy white paper on medicinal cannabis. As Principal Consultant at FreshLeaf Analytics, Rhys leads the FreshLeaf team and is responsible for business development and project delivery.
Dr Katrina Green is a medical science lecturer in the School of Medicine, University of Wollongong and a scientist at the Centre for Translational Neuroscience, Illawarra Health and Medical Research Institute. Dr Green's research aims to improve the pharmacological treatment of mental illness and to promote healthy aging, with a particular interest in exploring the potential of cannabinoids as novel therapeutics. Dr Green leads a research team that were the first to discover the therapeutic benefits of cannabidiol (CBD) on cognition (learning and memory) in a rodent model of schizophrenia. These findings are particularly important as cognitive impairment in schizophrenia is largely untreatable with current antipsychotic medications.
Tony Adcock is Executive Chairman of Agri-Tech company Food, Fibre & Land International Group Pty Ltd (FFLI) a group that grows broadacre industrial hemp for the Building and Construction industry, Food and Beverage industry, Cosmeceutical, Aromatherapy and Aromachology industries. In addition, FFLI has business in the land reclamation and mine rehabilitation industry. FFLI is an advocate of contemporising the federal legislation of CBD in the nutrition, health and well- being industries to allow economic opportunities for Australia.